This month we’re bringing updates to help improve the usability of our Immuno-oncology Portal for patients and all users! You can now discover ECPC’s IOP in an even more patients-led and interactive way.
The Immuno-oncology Portal provides you with updated information on availability and reimbursement for the latest immuno-therapies approved by European Medicines Agency in all EU Member States. We have also included updated information on the side-effects related to immunotherapies and how to manage them.
The European Cancer Patient Coalition’s has created an immuno-oncology platform, which provides valuable and practical information on cancer immunotherapies and immuno-oncology treatments for people with cancer across Europe. The immuno-oncology platform aims to provide people affected by cancer with up-to-date, accessible information about cancer immuno-oncology therapy – treatments, which use the immune system to fight cancer.
The portal focuses particularly on the newest type of cancer immunotherapy: immuno-oncology treatments, as these have shown very promising results in patients and are now available to treat a number of different cancers.
Find now which cancer immunotherapies are approved and available in your country, as well as whether they are reimbursed!
The European Cancer Patient Coalition designed the IOP following two guiding principles:
• Patient-centeredness: the Portal aims to empower patients and caregivers, therefore its content must be simple, understandable, yet informative;
• Scientific accuracy: all the information on the Portal must be scientifically correct, objective and free from bias. ECPC is one of Europe’s few patients’ organisations actively involved in scientific research. We strongly believe in the concept of patients as “co-researchers”. This is why we understand and value the contribution of scientific experts to produce our information material, including the Immuno-Oncology Portal.
The European Cancer Patient Coalition in collaboration with the European Expert Group on Immuno-Oncology has also produced a Guide for Patients on Immuno-Oncology. The guide is available in 21 languages, including Bulgarian, Croatian, Czech, Danish, Dutch, English, Irish, Estonian, French, Greek, Hungarian, Italian, Latvian, Lithuanian, Polish, Portuguese, Romanian, Slovenian, Spanish, Swedish and Turkish.
This guide was developed to help patients understand more about immuno-oncology therapies.
Let us know what you think!
As always, ECPC is taking patient-led initiatives and we are always interested in hearing your feedback.
For more information on Immuno-oncology visit our page here.